BeOne Medicines Ltd.
Close on Oct 19, 2026
- Market cap
- $557.24B
- P/E (TTM)
- 860.9
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 5, 2026 | Before market open | $1.71B | $0.16 | $3.84 |
| Q1 FY2026 Ended Mar 31, 2026 | Apr 14, 2026 | During market hours | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 26, 2026 | Before market open | $1.50B | $0.58 | $1.95 |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | Before market open | $1.40B | $1.09 | $2.65 |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 6, 2025 | Before market open | $1.32B | $0.84 | $2.25 |
| Q1 FY2025 Ended Mar 31, 2025 | Apr 28, 2025 | Before market open | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 27, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | Before market open | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 7, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | Apr 26, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 26, 2024 | Before market open | – | – | – |
Company guidance
Outlook given with results on Aug 5, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Diluted ADS outstanding | full year 2026 | 118 | New |
| Other income (expense) | full year 2026 | $25.00M to $50.00M | New |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements BeOne Medicines filed with the SEC
Key Differences between U.S. GAAP and PRC GAAP
Results of operations · EX-99.1 to Form 8-K
BeOne Medicines Announces Second Quarter 2026 Financial Results and Business Updates
Results of operations · EX-99.1 to Form 8-K
BeOne Medicines’ BEQALZI ™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma
Other events · EX-99.1 to Form 8-K
BeOne Medicines Announces First Quarter 2026 Financial Results and Business Updates
Results of operations · EX-99.1 to Form 8-K
Key Differences between U.S. GAAP and PRC GAAP
Results of operations · EX-99.1 to Form 8-K
BeOne Medicines Announces Fourth Quarter and Full Year 2025 Financial Results, Highlighting Global Success of BRUKINSA and Foundational Oncology Leadership
Results of operations · EX-99.1 to Form 8-K
BeOne Medicines Announces Third Quarter 2025 Financial Results and Business Updates
Results of operations · EX-99.1 to Form 8-K
Key Differences between PRC GAAP and U.S. GAAP
Results of operations · EX-99.1 to Form 8-K
BeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 Million
Material agreement · New financial obligation · Regulation FD disclosure · EX-99.1 to Form 8-K
BeOne Medicines Announces Second Quarter 2025 Financial Results and Business Updates
Results of operations · EX-99.1 to Form 8-K
BeiGene Announces First Quarter 2025 Financial Results and Business Updates
Results of operations · EX-99.1 to Form 8-K
Key Differences between PRC GAAP and U.S. GAAP
Results of operations · EX-99.1 to Form 8-K
BeiGene Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates
Results of operations · EX-99.1 to Form 8-K
BeiGene Announces Third Quarter 2024 Financial Results and Corporate Updates
Results of operations · Other events · EX-99.1 to Form 8-K
Key Differences between PRC GAAP and U.S. GAAP
Results of operations · EX-99.1 to Form 8-K
BeiGene Enters Next Phase of Global Growth with Announcement of Second Quarter 2024 Financial Results and Corporate Updates
Results of operations · Other events · EX-99.1 to Form 8-K
BeiGene Announces Appointment of Aaron Rosenberg as Chief Financial Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
BeiGene Reports First Quarter 2024 Financial Results and Business Updates
Results of operations · Other events · EX-99.1 to Form 8-K
Key Differences between PRC GAAP and U.S. GAAP
Results of operations · EX-99.1 to Form 8-K
BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
Other events · EX-99.1 to Form 8-K
BeiGene Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
Results of operations · Other events · EX-99.1 to Form 8-K
BeiGene Continues Global Growth with Third Quarter 2023 Financial Results and Business Updates
Results of operations · Other events · EX-99.1 to Form 8-K
BRUKINSA ® Receives Positive Recommendation from NICE in U.K. for Adult Patients with Chronic Lymphocytic Leukemia
Other events · EX-99.1 to Form 8-K
BeiGene Announces Positive Regulatory Updates in Europe and the U.S. After Recently Regaining Global Rights for TEVIMBRA ®
Other events · EX-99.1 to Form 8-K
Key Differences between PRC GAAP and U.S. GAAP
Results of operations · EX-99.1 to Form 8-K
BeiGene Accelerates Global Momentum with Strong Second Quarter 2023 Financial Results
Material agreement · Agreement terminated · Results of operations · Other events · EX-99.1 to Form 8-K
BeiGene Announces Positive CHMP Opinion for Tislelizumab as a Treatment for Advanced or Metastatic ESCC
Other events · EX-99.1 to Form 8-K
BeiGene Highlights Promising Data from Blood Cancer Portfolio and Pipeline at the European Hematology Association Hybrid Congress
Charter or bylaw amendment · Shareholder vote results · Other events · EX-99.1 to Form 8-K
BeiGene Highlights Significant BRUKINSA ® (zanubrutinib) Data at the 17 th International Conference on Malignant Lymphoma
Charter or bylaw amendment · Shareholder vote results · Other events · EX-99.2 to Form 8-K
BeiGene Presentations at the 2023 ASCO Annual Meeting Reinforce Promise Across Oncology Portfolio
Other events · EX-99.1 to Form 8-K
BeiGene Receives New Approvals for BRUKINSA ® (zanubrutinib) in China
Other events · EX-99.1 to Form 8-K
BeiGene Reports First Quarter 2023 Financial Results and Corporate Developments
Results of operations · Other events · EX-99.1 to Form 8-K